Antiretroviral Therapy: Panel Discussion
|
|
- Adrian Burke
- 5 years ago
- Views:
Transcription
1 disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none Questions What to start in an ART-naïve, with/without labs What to start if M184V alone? INSTI resistance New uses for old(er) drugs (rilpivirine, atazanavir)? Using fewer than 3 drugs Initial ART in pregnant women How will might soon-to-arrive ARVS change your initial management Treatment modification for (multiple) comorbidities, deintensification Question: in the era of Test and Treat, what regimen would you choose for an ARV-naïve patient without resistance testing available? 1
2 Case 1. 24, female, newly HIV+ : Lab-based Ag/Ab (+), differentiation Ab(-), HIV RNA 1.2 million c/ml CD4, scr, HLA-B*571, genotype, INSTI genotype all pending. Urine HCG(-); has an IUD No comorbidities Case 1: panelists, which regimen(s) for ARVnaïve patient who wants test-and-treat? 1. Elvitegravir/cobi/FTC/TAF 2. Darunavir 8mg QD + ritonavir 1mg QD + FTC/(TAF or TDF) 3. Raltegravir 12mg QD + FTC/(TAF or TDF) 4. Dolutegravir/abacavir/3TC 5. Dolutegravir + FTC/(TAF or TDF) 6. Rilpivirine/FTC/(TAF or TDF) 7. Dolutegravir + 3TC Recommended initial ART regimens reclassified in DHHS OCT217 I. For most people with HIV INSTI + 2 NRTIs 1. DTG/ABC/3TC if HLA-B*571 negative 2. (DTG or RAL) + FTC/tenofovir 3. Elvitegravir/cobicistat/FTC/tenofovir Recommended initial ART regimens reclassified in DHHS OCT217 II. For certain clinical situations 1. Boosted PI + 2 NRTIs In general, DRV preferred over ATV No distinction between boosting agents (rtvvs cobi) 2 NRTIs can be (FTC or 3TC) + (tenofovir or ABC) ABC only if HLA-B*571 negative Boosted ATV + ABC/3TC only if HIV RNA<1, c/ml 2. NNRTI + 2 NRTIs 1. EFV + (FTC or 3TC) + tenofovir 2. RPV/FTC/tenofovir only if HIV RNA<1, c/ml and CD4>2 cells/mm3 3. INSTI + 2 NRTIs 1. RAL + ABC + (3TC or FTC) only if HLA-B*571 negative and HI RNA<1, c/ml 4. If TDF, TAF and ABC cannot be used 1. DRV/r + RAL 4mg BID only if HIV RNA<1, c/ml and CD4>2 cells/mm3 2. LPV/r BID + 3TC BID 2
3 Case 2 Question: (How) does presence of M184V affect your choice of initial ART? 3, MSM, lab-based Ag/Ab(+) differentiation Ab HIV-1(+) at his most recent PrEP visit 3 weeks ago. Had heard about French study and was taking Truvada before and after sex, with some of his partners. Stopped altogether after testing HIV(+) CD4 55 cells/mm3, HIV RNA 5, c/ml, scr.9, Hepatitis B sag(-), HLA-B*571(-) GT: M184M/V Case 2: Panelists, Choice of initial therapy with M184V? 1. Dolutegravir/abacavir/3TC 2. Elvitegravir/cobicistat/FTC/(TAF or TDF) 3. Elvitegravir/cobicistat/FTC/(TAF or TDF) + DRV 4. Dolutegravir + FTC/(TAF or TDF) 5. Darunavir 8mg QD + ritonavir 1mg QD + FTC/(TAF or TDF) 6. Darunavir/cobi + FTC/(TAF or TDF) DAWNING: DTG Effective Even With Partially Active Background Regimen Randomized, open-label phase IIIb study in which pts in resourcelimited settings with virologic failure on NNRTI + 2 NRTIs treated with DTG + 2 NRTIs or LPV/RTV + 2 NRTIs (N = 627) Pts could not have primary resistance to INSTIs or PIs; pts required to receive 1 fully active NRTI Baseline NRTIs: ZDV + 3TC, 4%; TDF + 3TC or FTC, 42%; TDF + ZDV, 12%; ABC + 3TC, 2% Pts (%) n/n = HIV-1 RNA < 5 copies/ml, Wk 24 (ITT-E) / / 312 Overall* *Treatment difference: 13.8% (95% CI: 7.3% to 2.3%; P <.1) 74 45/ / 64 DTG + 2 NRTIs LPV/RTV + 2 NRTIs / 251 < 2 Fully Active NRTIs 73 18/ 248 Aboud M, et al. IAS 217. Abstract TUAB15LB. 3
4 Question(s): How do you interpret results of the GenoSure Archive assay when they suggest resistance in a patient with an undetectable VL? How comfortable are you with dolutegravir pseudomonotherapy? Case 3: 54 yo man, homeless, heterosexual but no sex in 25 years. Recently moved to SF from LA HCV ab(+) GT1a/1b; TC 153, H29, L62, TG312; scr.8, Sulfa allergy HIV(+) and on treatment since Prior regimens unknown, but reports having undetectable VL ever since since viral loads could be measured, and CD4 never <2. No h/o OIs. Current VL <2, CD4=816 Currently on DRV/ABC/3TC x 2 years I take it as many times a week as I can; records from LA clinic state he takes it 3x/week. He says will only take QD regimen. GenoSure Archive: NRTI: M41L, D67N, M184M/V, L21W T215Y; NNRTI: none; PI: K2R, M36I, I62V Case 3: Virologic suppression on DTG/ABC/3TC with ABC and 3TC resistance mutations by DNA testing 1. DTG/ABC/3TC (1 QD) 2. DTG + FTC/TAF (2 QD) 3. DRV/Cobi + DTG (2 QD) 4. DTG + RPV (2 QD) 5. E/C/F/TAF + DRV (2 QD) 6. Something else Question: What ARVs to use in the setting of resistance to INSTIs and NRTIs? GenoSure Archive: NRTI: M41L, D67N, M184M/V, L21W T215Y; NNRTI: none; PI: K2R, M36I, I62V; INSTI: none 4
5 Case 4: 31, MSM, HIV+ 27, BL HIV RNA > 1,; baseline GT= wild-type, HLA-B*571(-); nadir CD4 189 EFV/FTC/TDF ->rash-> ATV/r + FTC/TDF-> jaundice, total Bili 9. RAL + FTC/TDF with intermittent suppression until persistent viremia in 5/217: HIV RNA 4136 c/ml, CD4 244 cells/mm3 GT RT: M184V, K65R; PI: none; INSTI: G14S, Q148H. Trofile = R5 virus Audience: if you prescribe ART, have you encountered patients who developed INSTIresistance on Raltegravir or Elvitegravir? 1. Yes 2. No Case 4: panelists: which of the following would you include in a regimen for INSTI (G14S, Q148H) and NRTI (K65R, M184V) resistance: 1. dolutegravir 5mg BID 2. darunavir 6 BID + ritonavir 1 BID 3. darunavir 8 QD + ritonavir 1 QD 4. etravirine 2mg BID 5. etravirine 4mg QD 6. rilpivirine 25mg QD 7. FTC/TAF 1 tab QD 8. ABC/3TC 1 tab QD Question: What would you use/not use for initial ART in a woman diagnosed with HIV during pregnancy? Feel free to use coformulations if available 5
6 Case 5: initial ART for pregnant woman 32 y.o. woman, B-HCG(+) 6 months ago, LMP 7 months ago HIV+ by Ag/Ab and differentiation Ab 4 days ago Last (-)HIV test: 6 months ago Wants to keep pregnancy HIV RNA pending, GT pending, CD4 count 42 cells/mm3, HLA- B*571(-) CrCl>6ml/min Case 5: 1 st line ART for pregnant woman, rapid start, 3 rd trimester 1. Dolutegravir/abacavir/3TC 2. Dolutegravir + FTC/TAF 3. Raltegravir 4mg BID + FTC/TDF 4. Elvitegravir/cobi/FTC/TDF 5. Efavirenz/FTC/TDF 6. Atazanavir 3mg QD+ ritonavir 1mg QD + FTC/TDF QD 7. Darunavir 6mg BID + ritonavir 1mg BID + FTC/TDF Antiretroviral Agents and Pregnancy Preferred NRTI NNRTI PI Abacavir/lamivudine OR Emtricitabine*/tenofovir Alternative Zidovudine/LamivudineZi Efavirenz OR Rilpivirine plus preferred 2- NRTI Insufficient data in pregnancy Do not use in pregnancy Emtricitabine/tenofovir alafenamide (TAF/FTC) ABC/AZT/3TC as complete regimen; d4t, ddi Etravirine, Nevirapine *Or lamivudine. 1May be initiated after the first 8 weeks of pregnancy. Evidence of human fetal risk; Pregnancy Category D. Atazanavir/r 3 Darunavir/r plus preferred 2-NRTI Lopinavir/r plus preferred 2-NRTI Tipranavir, Fosamprenavir/ Indinavir/ Saquinavir/ Rttonavir alone, Nelfinavir Entry Inhibitor Maraviro c, T2 2Contraindicated with CD4+ counts >25/mm3 due to potential for liver toxicity. 3Theoretical concern for hyperbilirubinemia. 4Co-formulated with cobicistat/emtricitabine/tenofovir DF. Note: no data on use of cobicistat in pregnancy and can not be recommended for ART-naïve pregnant women at this time. DHHS. Revision October 16, 216. Integrase Inhibitor Raltegravir plus preferred 2- NRTI backbone Dolutegravir plus preferred 2-NRTI Elvitegravir/co bicistat 23 Tsepamo: Birth Outcomes When Initiating Firstline DTG vs EFV in Pregnancy Prospective cohort study in HIV-infected women in Botswana initiating ART with EFV/FTC/TDF vs DTG/FTC/TDF while pregnant (N = 5438) Adverse Birth Outcomes, n (%) Any Severe DTG (n = 845) 291 (34.4) 92 (1.9) Zash R, et al. IAS 217. Abstract MOAX22LB. EFV (n = 4593) 166 (35.) 519 (11.3) arr* (95% CI) 1. (.9-1.1) 1. (.8-1.2) Stillbirth 18 (2.1) 15 (2.3).9 (.6-1.5) Neonatal death (< 28 days) 11 (1.3) 6 (1.3) 1. (.5-1.9) Preterm birth (< 37 wks) Very preterm (< 32 wks) SGA (< 1th percentile weight) Very SGA (< 3rd percentile weight) 149 (17.8) 35 (4.2) 156 (18.7) 51 (6.1) 844 (18.5) 16 (3.5) 838 (18.5) 32 (6.7) *For DTG vs EFV; adjusted for maternal age, education, gravida. 1. (.8-1.1) 1.2 (.8-1.7) 1. (.9-1.2).9 (.7-1.2) Few first-trimester ART exposures (DTG, n = 116; EFV, n = 396); most second/third trimester Only 1 major congenital abnormality observed (skeletal dysplasia in EFV-exposed group) ABO risks similar when initiating first-line DTG vs EFV in pregnancy 6
7 Case 6: new drugs/strategies for first line in 218 Question: It s December 9, 218. How are you thinking about using new ARVs/treatment strategies for treatment-naïve patients? 51, newly confirmed HIV+ by CDC algorithm 2 weeks ago, last HIV(-) 2 years ago when he stopped PrEP ( wasn t having that much sex ) History of depression, not currently being treated Hypertension, controlled on Lisinopril HIV RNA 12, c/ml; CD4 count 375 cells/mm3; HLAB*571(-), genotype = wild-type egfr>6 TC 18 HDL 34 LDL 12 TG 2 Case 6: panelists, new drugs/strategies for initial therapy in dolutegravir/abacavir/3tc (1 tab daily) 2. bictegravir/ftc/taf (1 tab daily) 3. doravirine/3tc/tdf (1 tab daily) 4. DRV/c/FTC/TAF (1 tab daily) 5. dolutegravir + 3TC (2 tabs daily) 6. dolutegravir/rilpivirine (1 tab daily) Question: How do you balance virologic efficacy and cardiovascular, renal comorbidities in treatment simplification? 7
8 Case 7: 58, HIV(+) since 199s peak HIV RNA >1, c/ml; nadir CD4 <5 cells/mm3 History of exposure to nevirapine, d4t, 3TC, nelfinavir, with periods of meth use, intermittent viremia, culminating in virologic failure with (list of mutations): Suppressed in 26 with unboosted ATV (due to hyperlipidemia, recurrent pancreatitis), TDF, 3TC, T-2. virus is mixed CCR5/CXCR4 tropic. TDF switched to ABC due to CKD in 28; CrCl currently 51. Lipids are TC167 H28 L??? TG783 on atorvastatin and fenofibric acid CV risk score: Currently suppressed on ATV 4 BID, RAL 4 BID, ABC/3TC Case 7: (how) would you modify his regimen 1. ATV BID + RAL BID + ABC 6 mg/3tc 3mg QD (no change) 2. DRV/r + DTG + 3TC 3. DRV/r + DTG + FTC/TAF 4. DTG + RPV 5. DTG + DRV/r 6. ATV/r + 3TC 7. EVG/cobi/FTC/TAF + DRV Thanks! D:A:D: Exposure to ATV/RTV or DRV/RTV and Risk of CVD Prospective analysis of pts followed from 29 to earliest CVD, last visit + 6 mos, or 2/1/216 (N = 35,711) 1157 pts (3.2%) developed CVD (MI, stroke, sudden cardiac death, invasive CV procedure) Cumulative exposure to DRV/RTV, but not ATV/RTV, associated with increased CVD risk in multivariate analysis: 59% risk increase per 5 yrs of DRV/RTV Association does not appear to be mediated through dyslipidemia, in contrast with first-generation PIs CVD Risk per 5 Yrs of ARV Exposure, IRR (95% CI) Model ATV/RTV DRV/RTV Univariate 1.25 ( ) 1.93 ( ) Multivariate Baseline adjusted* 1.3 ( ) 1.59 ( ) Time-updated adjusted* 1.1 ( ) 1.53 ( ) *Adjusted for: BMI, CKD, DM, CD4, dyslipidemia. CVD Incidence Rate Ratio (95% CI) Relationship Between 5-Yr Exposure to ARVs and CVD No exposure Univariate MV: BL adj model MV: Time-updated adj model ATV/RTV DRV/RTV Ryom L, et al. CROI 217. Abstract 128LB. 8
9 D:A:D: Cumulative Exposure to ARVs Associated With Increased CKD Risk CKD Risk by Yrs of ARV Exposure, Incidence Rate Ratio* (95% CI) Drug 1 Yr 5 Yrs TDF ATV + RTV LPV/ RTV 1.14 ( ) 1.2 ( ) 1.11 ( ) Mocroft A, et al. Lancet HIV. 216;3:e23-e ( ) 2.44 ( ) 1.66 ( ) *Multivariate analysis. For each value, P <.1 Incidence Rate Ratio (95% CI) P value (univariate) TDF <.1 P value <.1 (multivariate) ATV + RTV <.1 <.1 Univariate Multivariate LPV/RTV <.1 <.1 55 Clinic: Real-World Virologic Suppression by Regimen in Pts With M184V Mutation Retrospective cohort study using medical records of new pts presenting to University of Louisville outpatient HIV clinic from January 23 to July 216 HIV-1 RNA < 2 c/ml (%) Analysis of tx-naive (2%) or tx-experienced (98%) pts with M184V mutation: N = 1 pts, 167 regimens Regimens With < 3 Fully Active Drugs P =.13 P = P =.11* 1 P = HIV-1 RNA < 2 c/ml (%) / 11/ 59/ 21/ 56/ 17/ 3/ 4/ 1/ 7/ n/n = n/n = < 3 3 PI INSTI PI INSTI PI INSTI RAL EVG Fully Active Drugs Overall HIV-1 RNA HIV-1 RNA < 1, c/ml 1, c/ml *Predefined noninferiority criteria not met for regimens with < 3 vs full active drugs. Kirkpatrick L, et al. IDWeek 217. Abstract / 4 DTG EARNEST: Boosted PI + NRTIs Noninferior to Boosted PI + RAL Randomized, open-label phase III trial in which pts in sub-saharan Africa with virologic failure on NNRTI + 2 NRTIs treated with LPV/RTV + RAL, LPV/RTV NRTIs, or LPV/RTV monotherapy* (N = 1277) HIV-1 RNA < 4 copies/ml, Wk 144 [2] HIV-1 RNA < 5 copies/ml, Wk 96 [1] 1 Pts (%) P <.1 73 LPV/RTV + 2/3 NRTIs (n = 426) LPV/RTV + RAL (n = 433) LPV/RTV monotherapy (n = 418) *Pts had no prior PIs; pts receiving monotherapy received 12 wks of LPV/RTV + RAL. Paton NI, et al. N Engl J Med. 214;371: Paton, NI, et al. ACHA Pts (%) LPV/ LPV/ RTV + RTV LPV/RTV + NRTI RAL (Number of Active NRTIs) Study 119: Switch to EVG/COBI/FTC/TAF + DRV in Treatment-Experienced Pts Multicenter, open-label, randomized phase III trial Primary endpoint: HIV-1 RNA < 5 copies/ml at Wk 24 Treatment-experienced pts, HIV-1 RNA < 5 c/ml for 4 mos on DRVcontaining ART, with history of drug resistance* and egfr 5 ml/min (N = 135) Wk 24 39% pts receiving 6 pills/day at baseline Switch to EVG/COBI/FTC/TAF + DRV 8 mg QD (n = 89) Baseline ART (n = 46) Wk 48 EVG/COBI/FTC/TAF + DRV 8 mg QD (n = 46) Huhn GD, et al. IDWeek 215. Abstract 726. Huhn GD, et al. J Acquir Immune Defic Syndr. 217;74: Wk 144 *Resistance to 2 ARV classes, including 3 thymidine analogue mutations and/or K65R, but not integrase inhibitors (unless currently receiving RAL, EVG, or once-daily DTG), and no DRV resistance. 9
10 Study 119: Virologic Suppression After Switch to EVG/COBI/FTC/TAF + DRV Wk 24 Virologic Efficacy Wk 48 Virologic Efficacy Summary Points EVG/COBI/FTC/TAF + DRV Baseline ART 1 94 EVG/COBI/FTC/TAF + DRV Baseline ART Pts (%) Treatment difference: 5.3% (95% CI: -3.4% to 17.4%; P =.23) Pts (%) Treatment difference: 18.3% (95% CI: 3.5% to 33.%; P =.4) 2 HIV-1 RNA < 5 c/ml Virologic Failure No Data 2 HIV-1 RNA < 5 c/ml 11 2 Virologic Failure 13 3 No Data Huhn GD, et al. J Acquir Immune Defic Syndr. 217;74:
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationDisclosures. Goals/Format. Patient 1 12/8/18. Antiretroviral Therapy Management. Harry Lampiris: None. Gabriel Chamie: None.
Disclosures Antiretroviral Therapy Management Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 6, 2018 Harry Lampiris, MD, 1 Gabriel Chamie, MD, MPH 2 Susa Coffey, MD, 2 and Vivek
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationD:A:D: Cumulative Exposure to DRV/r Increase MI Risk
D:A:D: Cumulative Exposure to DRV/r Increase MI Risk 20.0-15.0-10.0-5.0-4.0-3.0-2.0-1.0- Unadjusted CVD rate ratios per 5 years additional exposure: ATV/r 1.25 [1.10-1.43] and DRV/r 1.93 [1.63-2.28] Adjusted*
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationOptimizing ARV For Women
Optimizing ARV For Women Kathleen E. Squires, MD W Paul and Ida H Havens Professor of Infectious Diseases Director, Division of Infectious Diseases Sidney Kimmel Medical College of Thomas Jefferson University
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More information5/2/2016. Antiretroviral Therapy (ART) Strategies: A Case-Based, Panel Discussion
Antiretroviral Therapy (ART) Strategies: A Case-Based, Panel Discussion Joseph J. Eron, Jr, MD Professor of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina FORMATTED: 4/13/216
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationARV Update: 2016 and Beyond Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital
ARV Update: 2016 and Beyond Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital Disclosures Scientific Advisory Panels: Gilead, Thera technologies, Merck,
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationWhat s New. In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group
What s New In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group Guidelines for our Online Meeting Room You will be listening to
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationAntiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion
Slide 1 of 51 Antiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More information30 Years of HIV: An Update on Treatment Guidelines and Beyond
8/3/212 Conflict of Interest Declaration 3 Years of HIV: An Update on Treatment Guidelines and Beyond Blake Max, PharmD, AAHIVE Clinical Associate Professor University of Illinois at Chicago College of
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationHIV: Approach to the Treatment-Naïve Patient
HIV: Approach to the Treatment-Naïve Patient Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Approach
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More information